GSK Consumer Healthcare slips 9% on strategic review of Horlicks

Shares of GlaxoSmithKline Consumer Healthcare fell 9 percent intraday Wednesday as parent company to carry out a strategic review of Horlicks.

GlaxoSmithKline Plc (GSK) intent to carry out a strategic review of GSK's Horlicks and its other consumer nutrition products which will include an assessment of its 72.45 percent shareholding in the company.

At 13:20 hrs GlaxoSmithKline Consumer Healthcare was quoting at Rs 6,100, down Rs 551.65, or 8.29 percent on the BSE.

The share touched its 52-week high Rs 6,888.45 and 52-week low Rs 4,856.05 on 22 February, 2018 and 29 September, 2017, respectively.

Currently, it is trading 11.45 percent below its 52-week high and 25.62 percent above its 52-week low.